Compare Oklo Inc (OKLO) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oklo Inc vs Tango Therapeutics Inc. — how do they compare? Oklo Inc trades at $28.05 (market cap $5.91B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Oklo Inc is the larger of the two by market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Oklo Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oklo Inc for 33 Days and Tango Therapeutics Inc. for 0 Days on average.
| OKLO | TNGX | |
|---|---|---|
Market Cap | $5.91B | $3.75B |
Volume | 8,898,651 | 9,619,106 |
Sector | Utilities | Health |
52-Week High | $171.56 | $32.90 |
52-Week Low | $29.04 | $7.50 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $3.45B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OKLO trades at $31.78, down 1.33% on the day, with a bearish technical signal despite oversold RSI readings. The company shows no revenue in 2025 and a net loss of $105.66 million, with negative profit margins and ROE. Recent news highlights competition in the nuclear sector and OKLO's $1 billion stock sale, while analyst consensus remains strongly bullish with a $78.63 price target.
OKLO presents high-risk, high-reward potential as an early-stage nuclear company. The bullish analyst outlook and strategic project pipeline offer upside, but significant execution risks, cash burn, and competitive pressures require careful consideration. Investor sentiment is mixed amid operational challenges and dilution concerns.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
